{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T02:27:37Z","timestamp":1688005657883},"reference-count":28,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1111\/jcpt.12572","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T13:46:38Z","timestamp":1498743998000},"page":"776-779","source":"Crossref","is-referenced-by-count":2,"title":["Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma"],"prefix":"10.1155","volume":"42","author":[{"given":"P. N.","family":"Tran","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology; Department of Medicine; Chao Family Comprehensive Cancer Center; University of California Irvine School of Medicine; Orange CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. C.","family":"Pinter-Brown","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology; Department of Medicine; Chao Family Comprehensive Cancer Center; University of California Irvine School of Medicine; Orange CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"10.1111\/jcpt.12572-BIB0001|jcpt12572-cit-0001","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1111\/jcpt.12572-BIB0002|jcpt12572-cit-0002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1111\/jcpt.12572-BIB0003|jcpt12572-cit-0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/0971-5851.76197","article-title":"Targeting mTOR pathway: a new concept in cancer therapy","volume":"31","author":"Advani","year":"2010","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1111\/jcpt.12572-BIB0004|jcpt12572-cit-0004","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrd2924","article-title":"Everolimus","volume":"8","author":"Atkins","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jcpt.12572-BIB0005|jcpt12572-cit-0005","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","article-title":"mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor","volume":"15","author":"Lane","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12572-BIB0006|jcpt12572-cit-0006","unstructured":"Novartis Pharmaceutical Co Afinitor and Afinitor Disperz (everolimus) East Hanover, NJ Novartis Pharmaceutical Co 2016"},{"key":"10.1111\/jcpt.12572-BIB0007|jcpt12572-cit-0007","unstructured":"Novartis Pharmaceutical Co Zortress (everolimus) East Hanover, NJ Novartis Pharmaceutical Co 2016"},{"key":"10.1111\/jcpt.12572-BIB0008|jcpt12572-cit-0008","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1111\/jcpt.12572-BIB0009|jcpt12572-cit-0009","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12572-BIB0010|jcpt12572-cit-0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/jco.2012.30.5_suppl.356","article-title":"Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: results from EXIST-2","volume":"30","author":"Bissler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12572-BIB0011|jcpt12572-cit-0011","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12572-BIB0012|jcpt12572-cit-0012","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/FTD.0000000000000294","article-title":"Management of everolimus and voriconazole interaction in lung transplant patients","volume":"38","author":"Mac\u00edas","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12572-BIB0013|jcpt12572-cit-0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jcpt.12234","article-title":"Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient","volume":"40","author":"Lecefel","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12572-BIB0014|jcpt12572-cit-0014","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12572-BIB0015|jcpt12572-cit-0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfn574","article-title":"Sirolimus interacts with pathways essential for podocyte integrity","volume":"24","author":"Letavernier","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12572-BIB0016|jcpt12572-cit-0016","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/ndt\/gfl340","article-title":"Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy","volume":"21","author":"Keller","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12572-BIB0017|jcpt12572-cit-0017","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1600-6143.2005.01047.x","article-title":"Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys","volume":"5","author":"Sartelet","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/jcpt.12572-BIB0018|jcpt12572-cit-0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trim.2010.05.003","article-title":"Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway","volume":"23","author":"Oroszl\u00e1n","year":"2010","journal-title":"Transpl Immunol"},{"key":"10.1111\/jcpt.12572-BIB0019|jcpt12572-cit-0019","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1681\/ASN.2011070690","article-title":"Inhibition of MTOR disrupts autophagic flux in podocytes","volume":"23","author":"Cin\u00e0","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jcpt.12572-BIB0020|jcpt12572-cit-0020","doi-asserted-by":"crossref","first-page":"F569","DOI":"10.1152\/ajprenal.00180.2012","article-title":"The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response","volume":"303","author":"Kirsch","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1111\/jcpt.12572-BIB0021|jcpt12572-cit-0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev"},{"key":"10.1111\/jcpt.12572-BIB0022|jcpt12572-cit-0022","first-page":"404","article-title":"Causes and consequences of proteinuria following kidney transplantation","volume":"31","author":"Su\u00e1rez","year":"2010","journal-title":"Nefrologia"},{"key":"10.1111\/jcpt.12572-BIB0023|jcpt12572-cit-0023","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1111\/jcpt.12572-BIB0024|jcpt12572-cit-0024","unstructured":"\u015eahin G Ya\u015far N\u015e \u00c7ift\u00e7i E Yal\u00e7in AU Kiper H Nephrotic range proteinuria due to everolimus in a renal transplant recipient bir renal transplant hastasinda everolimusa ba\u011fli nefrotik d\u00fczeyde protein\u00fcri 2009 18 127 130"},{"key":"10.1111\/jcpt.12572-BIB0025|jcpt12572-cit-0025","first-page":"539","article-title":"Proteinuria associated with mTOR inhibitors after kidney transplant","volume":"12","author":"Guney","year":"2014","journal-title":"Exp Clin Transplant"},{"key":"10.1111\/jcpt.12572-BIB0026|jcpt12572-cit-0026","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12572-BIB0027|jcpt12572-cit-0027","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000201930","article-title":"Temsirolimus-induced glomerulopathy","volume":"76","author":"Izzedine","year":"2009","journal-title":"Oncology"},{"key":"10.1111\/jcpt.12572-BIB0028|jcpt12572-cit-0028","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1681\/ASN.2005121250","article-title":"Angiogenesis and endothelial cell repair in renal disease and allograft rejection","volume":"17","author":"Reinders","year":"2006","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12572\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:04Z","timestamp":1671818584000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12572","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,29]]}}}